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A
 
quarter of a century ago, it was proposed that veiled
cells in the lymph were antigen-bearing Langerhans’
cells (LCs) en route to the LN T cell area (1, 2). Extensive
investigations have since established that LCs are immature
dendritic cells (DCs) and that insults to the skin—including
exposure to contact sensitizers, bacteria, or UV light—
cause many of these cells to enter lymphatic vessels and
travel to LNs (3). During transit the cells undergo a pro-
gram of maturation events that take them from being
poorly immunogenic to being the most potent of all APCs
(3). Rapid transit of maturing DCs from the site of infec-
tion to the draining lymphoid tissue is likely to be critical
 
for quick initiation of the adaptive immune response. But how
do these cells migrate to lymphatics and subsequently into
the LN T zone? A flurry of recent studies (4–9) have impli-
 
cated chemokines and chemokine receptors in directing DC
migration, and now a study reported in this issue provides
strong evidence that one chemokine, secondary lymphoid
tissue chemokine (SLC), plays an important role in DC mi-
gration in vivo to T cell zones of LNs and spleen (10).
Chemokines are small basic proteins that engage seven
transmembrane receptors on responsive cells and promote
chemotaxis (11). First characterized for their role in attract-
ing cells to sites of inflammation, chemokines have more
recently been found to direct cell movements within lym-
 
phoid tissues. Two chemokines that have been suggested
 
to serve a homing function in the T cell compartment
are SLC/6Ckine (12–16) and EBV-induced molecule 1
ligand chemokine (ELC)/macrophage inflammatory pro-
 
tein (MIP)-3
 
b
 
 (17–19). SLC and ELC are structurally re-
lated chemokines and both bind the receptor CCR7 (20,
21). SLC is expressed at high levels by high endothelial
venules (HEVs) in LNs and at lower levels by a poorly de-
fined population of stromal cells in T cell areas of LNs,
spleen, and Peyer’s patches (13, 15, 16). ELC is made by a
subset of DCs, and possibly by other nonlymphoid cells, in
T cell areas of lymphoid tissue (19). Both chemokines are
efficacious attractants of T lymphocytes (19, 21) and both
can promote integrin activation on rolling lymphocytes
(13, 22). Together these findings have led to the notion
that SLC functions in recruitment of T cells across HEVs
into LNs and more generally in promoting T cell migration
into lymphoid T zones. ELC may work with SLC in re-
cruiting cells into the T zone and in the next step, in pro-
moting encounter between T zone DCs and T cells.
 
Mice carrying the paucity of lymph node T cells (
 
plt
 
)
 
mutation, a spontaneous mutation that arose on the DDD/1
strain background, have a defect in T cell homing into LNs
and splenic white pulp (23, 24). The expression pattern and
properties of SLC led Gunn et al. to consider it a candidate
for the 
 
plt
 
 gene, and this idea received a boost when map-
ping studies placed the 
 
plt
 
 mutation on a region of mouse
chromosome 4 syntenic to the region of human chromo-
some 9 that contains the linked SLC and ELC genes (12,
17, 24). Gunn et al. have now demonstrated that expres-
sion of SLC is defective in 
 
plt
 
 mice (10). This finding and
the prior T cell trafficking studies by Nakano et al. (23, 24)
together provide strong evidence that SLC is necessary for
homing of naive T cells across HEVs and into lymphoid T
cell areas (10). Expression of the potentially closely linked
ELC gene was also reduced in 
 
plt
 
 mice, although only par-
tially and possibly as a secondary effect of the defective SLC
expression (10). However, despite the mapping data and
absence of SLC mRNA at levels detectable by Northern
blot, sequence analysis of the SLC gene from 
 
plt
 
 mice has
failed so far to uncover a mutation that could be responsi-
ble for the loss of SLC expression (10). Mutation of a dis-
 
tant regulatory region remains a likely possibility, but until
such a mutation is found one must be cautious in conclud-
 
ing that defects in 
 
plt
 
 mice reflect solely a deficiency in SLC.
In situ hybridization analysis in wild-type mice demon-
strated that lymphatic endothelial cells in many tissues
make SLC (13). Taken together with its expression in LN
T cell areas, this finding suggested that SLC might have a
role in homing of DCs from peripheral tissues to lymphoid
T zones. Support for this possibility came in several impor-
tant studies over the last year showing that maturing DC
upregulate expression of CCR7 and chemotactically re-
spond to ELC (4, 6–9). At the time these studies were per-
formed, it had not been reported that SLC was a ligand for
CCR7. In vitro studies have since shown that transfection
of cells with CCR7 is sufficient to confer chemotactic re-
sponsiveness to SLC as well as ELC (20, 21), making it
likely that CCR7-expressing DCs migrate towards both
chemokines. By studying DCs in 
 
plt
 
 mice, Gunn et al. have
provided in vivo evidence of a role for SLC in directing
DC migration (10).
The number of DCs in the LNs of 
 
plt
 
 mice is reduced
approximately threefold compared with wild-type animals,
consistent with a DC homing defect (10). 1 d after skin 
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painting with the contact sensitizer FITC, the frequency of
FITC-bearing DCs in 
 
plt
 
 LNs was fourfold less than in
control LNs, providing evidence that SLC is needed for
DC migration from skin to LNs via afferent lymphatics
(10). The frequency of LCs in skin was indistinguishable in
 
plt
 
 and wild-type mice, so the next question was whether
SLC was required for DCs to enter lymphatic vessels. The
small size of mice makes it difficult to cannulate afferent
lymphatic vessels and perform the direct measurement of
veiled cell frequencies done so elegantly in larger animals
(1, 2). However, a method of tracking LC migration into
lymphatics has been developed in mice where ears are split
in half and incubated in vitro until many LCs begin to ma-
ture and migrate into dermal lymphatic vessels (25, 26).
LCs were found to enter the dermal lymphatic vessels of 
 
plt
 
mice with an efficiency that was indistinguishable from
controls (10). These studies provide evidence that SLC is
needed for efficient passage of DCs from lymphatic vessels
into LN T zones, but not for entry into the lymphatic ves-
sels themselves.
LCs are members in a family of tissue DCs, and almost
every tissue contains sentinel DCs (3). Although differences
between immature tissue DCs in different locations have
been reported, most tissue DCs have in common the pro-
pensity to emigrate to draining lymphoid tissues in response
to LPS, TNF, or IL-1 (3). All the DC types so far tested
upregulate CCR7 upon stimulation, making it likely that
they all use this receptor in order to migrate to lymphoid T
zones (4, 6–9). It remains to be investigated whether the
same directional cues are also involved in the homeostatic
flux of DCs from tissues to LNs that occurs in the absence
of stimulation (3). A subset of DCs in peripheral lymphoid
tissues, including lymphoid lineage DCs (27), may not de-
rive from peripheral tissues but instead may enter directly
from the blood (3). Some insight into the behavior of these
cells in 
 
plt
 
 mice is provided by findings in the spleen. Wild-
type mouse spleen contains a population of DCs in the T
zone that express high levels of DEC205 and that are
thought to be mostly of lymphoid lineage, and a popula-
tion of myeloid lineage DCs in the marginal zone that ex-
press little DEC205 (3). Exposure to LPS causes marginal
zone DCs to migrate rapidly into the splenic T zone (3). In
 
plt
 
 mouse spleen, the distribution of DCs is altered, with
fewer cells located inside white pulp cords (10). In addi-
tion, staining for the T zone DC marker DEC205 is sub-
stantially reduced, suggesting either that the number of
lymphoid lineage DCs is reduced or that DEC205 expres-
sion is dependent on normal organization of cells in a T
zone. LPS treatment of 
 
plt
 
 mice failed to cause DCs to con-
gregate in areas thought, by their proximity to arterioles, to
be T zones (10). These findings provide evidence that SLC
is needed for homing of multiple types of DCs to lymphoid
T cell areas.
SLC shares the CCR7 receptor with ELC, and an im-
portant issue still to be addressed is the relative contribution
of these two chemokines to DC homing to T cell areas.
ELC expression in 
 
plt
 
 mice is approximately threefold
lower than in wild-type controls (10). At least a fraction of
 
the ELC produced in lymphoid tissues comes from T zone
DCs (19), making it possible that the reduced ELC expres-
sion in 
 
plt
 
 LNs and spleen is secondary to lower numbers of
T zone DCs. Normal interactions between T cells and
ELC-producing cells, which are likely to be disrupted in 
 
plt
 
mice, might also be important in maintaining ELC expres-
sion. However, the possibility that the 
 
plt
 
 defect directly af-
fects ELC expression has not been ruled out. Whatever the
explanation, the reduced ELC levels may contribute to the
phenotype of 
 
plt
 
 mice. Reciprocally, the continued expres-
sion of significant amounts of ELC in these animals might
account for the incomplete block in DC recruitment to
LNs. Studies in CCR7-deficient mice and SLC- and ELC-
deficient mice are likely to help resolve the relative impor-
tance of SLC and ELC in DC and T cell homing to lym-
phoid T zones. It is interesting to consider that as ELC can
be made by T zone DCs and can attract antigen-bearing
peripheral DCs, this chemokine may have a novel function
promoting DC–DC encounters, possibly leading to the
passing of antigen between DCs and more efficient presen-
tation to T cells.
A model of the events in LC migration to the LN T
zone that incorporates the recent findings on chemokine
and chemokine receptor expression is presented in Fig. 1.
Immature DCs express a variety of inflammatory chemo-
kine receptors, including CCR1, CCR5, CCR6, and
CXCR1, which may participate in DC recruitment to in-
flamed tissues (4–9). Differential chemokine receptor ex-
pression may contribute selectivity in the recruitment pro-
cess, since CCR6, the MIP-3
 
a
 
 receptor, is expressed at
high levels by lung DCs and DCs derived in vitro from
CD34
 
1
 
 cord blood precursors but not by monocyte-derived
DCs (4, 7, 28). It seems likely that some chemokines often
thought of as inflammatory—as well as others still to be
characterized—help recruit immature DCs to become sen-
tinels in noninflamed tissues, a possibility supported by the
finding of constitutively expressed MIP-3
 
a
 
 in liver and
lung (29). Monocyte chemotactic protein 1 (MCP1) is ex-
pressed constitutively in many tissues (30), and although its
cognate receptor, CCR2, is not highly expressed by imma-
ture DCs, it is strongly expressed by monocytes (31). As re-
cent findings indicate that monocytes may differentiate into
DCs during migration into lymphatic vessels (32), MCP1
and CCR2 may make an important contribution to DC
trafficking.
The rapid upregulation of chemokine expression that
occurs at sites of inflammation should help recruit more
DC precursors to the site, but might also be expected to in-
terfere with the ability of antigen-bearing DCs to emigrate.
Hence, the recently observed rapid decrease in chemokine
receptor function during DC maturation, either by direct
downregulation (4–9) or by functional modulation as a re-
sult of intrinsic expression of chemokine (7), is likely to be
important in allowing the cells to move from the site (Fig.
1). Adhesion molecule changes may also be important for
emigration, including reduced expression of E-cadherin,
activation of 
 
a
 
6 integrins, and switching of CD44 isoforms
(3). In addition to these changes, it would seem likely that 
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attractant cues are needed to guide DCs to the lymphatic
vessels, and the expression of SLC in many lymphatic ves-
sels (13) suggests it has a role at this site. The failure to de-
tect any effect of the 
 
plt
 
 mutation on DC entry into dermal
lymphatics does not yet exclude a role for SLC, as the 
 
plt
 
mutation may be in a regulatory region of the SLC gene
and so may not fully disrupt SLC expression at all sites. The
possibility that ELC is made by lymphatic endothelium in
the skin has yet to be explored.
Once DCs have entered lymphatic vessels and become
veiled cells, how do they then move out into the T zone
parenchyma to become interdigitating DCs (Fig. 1)?
CCR7, SLC, and ELC can now be said to have a role and
CXCR4/stromal cell factor 1 (SDF1) might also contribute
(5–7), but what other molecules are needed for the cells to
move from the subcapsular sinus? Cells lining the sinus are
part of a larger network of fibroblastic reticular cells that
form cords and channels through the LN parenchyma (33).
What role does this network play in presenting chemokines
and other guidance cues to the migrating DCs? Within
lymphoid tissues, even within the T zone itself, DCs are
not evenly dispersed. What additional cues contribute to
subcompartmentalization of the cells? Finally, as DCs
themselves are being found to express an increasing array of
chemokines, to what extent do they contribute to the
overall organization of the lymphoid tissue? Could migrat-
ing DCs provide a homeostatic link between the severity of
a peripheral infection and the magnitude of increased lym-
phocyte retention that occurs in the draining lymphoid tis-
sue? As an understanding of the factors regulating DC mi-
gration to the T cell areas of lymphoid tissues has important
implications for many aspects of immunobiology, including
the development of new adjuvants and immunosuppres-
sants, we can be sure that answers to many of these ques-
tions will soon be unveiled.
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